### Indication
- **Anuria or oliguria**

### ATC codes
- **C03CA01**

### EMLc
- **Furosemide**

### Indication
- **ICD11 code:** MF51

### INN
- **Furosemide**

### Medicine type
- **Chemical agent**

### List type
- **Core**

### Additional notes
- The square box applies only to the listing of furosemide on the EML.

### Formulations
- **Parenteral:** General injections > IV: 10 mg per mL in 2 mL ampoule; 10 mg per mL in 5 mL ampoule
- **Oral:** Liquid: 20 mg per 5 mL (EMLc); 50 mg per 5 mL (EMLc)
- **Oral Solid** tablet: 40 mg; 20 mg

### EML status history
- First added in 1977 (TRS 615)
- Changed in 1979 (TRS 641)
- Changed in 2007 (TRS 950)
- Changed in 2021 (TRS 1035)
- Changed in 2023 (TRS 1049)

### Sex
- **All**

### Age
- **Also recommended for children**

### Therapeutic alternatives
- bumetanide (ATC codes: C03CA02)
- torasemide (ATC codes: C03CA04)

### Patent information
- Patents have expired in most jurisdictions
- Visit the [Wikipedia](https://en.wikipedia.org/wiki/Furosemide) page for more information on patents.

### Summary of evidence and Expert Committee recommendations
Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the addition of new strength formulations of furosemide (injection 10 mg/mL in 5 mL; tablet 20 mg (EML and EMLc); oral liquid 50 mg/5 mL (EMLc). The Committee also recommended the removal of furosemide 10 mg tablets from the EMLc.